Log in
Enquire now
CytomX Therapeutics

CytomX Therapeutics

A biotechnology company that develops Probodies, proteolytically-activated antibodies to treat cancer.

OverviewStructured DataIssuesContributors

Contents

cytomx.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
T cell
T cell
Therapeutics
Therapeutics
Oncology
Oncology
Biopharmaceutical
Biopharmaceutical
Therapy
Therapy
Cancer
Cancer
Biomedical engineering
Biomedical engineering
...
Location
United States
United States
South San Francisco, California
South San Francisco, California
0
San Francisco
San Francisco
B2X
B2B
B2B
CEO
‌
Sean McCarthy
0
Founder
Patrick Daugherty
Patrick Daugherty
AngelList URL
angel.co/cytomx-therapeutics
Pitchbook URL
pitchbook.com/profiles.../51019-21
Legal Name
CytomX Therapeutics, Inc.
Date Incorporated
2008
Number of Employees (Ranges)
51 – 2000
Email Address
henry@cytomx.com
Phone Number
+165051531850
Number of Employees
178
Full Address
151 Oyster Point Blvd, Suite 400 South San Francisco, CA 94080-1913, USA0
CIK Number
1,501,9890
Investors
Canaan
Canaan
Venrock
Venrock
Roche Venture Fund
Roche Venture Fund
Third Rock Ventures
Third Rock Ventures
DUNS Number
809851616
IRS Number
273,521,2190
Founded Date
2008
0
Fax Number
650-351-03530
Total Funding Amount (USD)
71,000,000
Latest Funding Round Date
August 2012
Competitors
Forbius
Forbius
0
Iconic Therapeutics
Iconic Therapeutics
0
Stock Symbol
CTMX0
Exchange
Nasdaq
Nasdaq
0
Glassdoor ID
1394997
Board of Directors
‌
Alan Ashworth
0
‌
Elaine Jones
0
‌
Halley Gilbert
0
‌
James R. Meyers
0
Mani Mohindru
Mani Mohindru
0
‌
Sean McCarthy
0
CFO
‌
Carlos Campoy
0
Key People
‌
Sean McCarthy
Latest Funding Type
Series B
Series B
NAICS Code
325,4120
CAGE Code
6Y2S40
Patents Assigned (Count)
49
Wellfound ID
cytomx-therapeutics
Country
United States
United States
Headquarters
San Francisco
San Francisco

Other attributes

Company Operating Status
Active
Contact Page URL
cytomx.com/contact/
SIC Code
2,8340
Ticker Symbol
CTMX

CytomX Therapeutics is a privately funded and publicly traded biotechnology company based in the South San Francisco, California and was founded in 2008 by Fred Gluck and Patrick Daugherty. It is a clinical stage oncology-focused biopharmaceutical company pioneering in a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform.

Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. CytomX's product pipeline includes cancer immunotherapies against clinically-validated targets. CX-072 and CX-188 are PD-L1 targeting Probody therapeutic. CX-2009 is an in-class Probody drug conjugate targeting CD166. All three are owned wholly by CytomX.

The company is also collaborating with other biopharmaceutical companies including AbbVie, Amgen, Bristol-Myers Squibb Company, and ImmunoGen, Inc. BMS-986249 is a CTLA-4 targeting Probody therapeutic partnered with Bristol Myers Squibb. CX-2029 is a DC71 targeting Probody drug conjugate partnered with AbbVie.

All products, except CX-188 are in various Phase 1/2 clinical trial progression. CX-2009 is currently being evaluated in its clinical trial, while CX-2009 and BMS-986249 are enrolling patients for the clinical studies.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

CytomX Therapeutics Announces Senior Management Appointments

CytomX Therapeutics Inc.

https://www.globenewswire.com/news-release/2019/02/05/1710570/0/en/CytomX-Therapeutics-Announces-Senior-Management-Appointments.html

Web

References

Find more companies like CytomX Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.